))
Episode 25: What to Know about Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)
Manage episode 377087447 series 3426844
Innhold levert av Learn Advocate Connect Neuroendocrine Tumor Society. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Learn Advocate Connect Neuroendocrine Tumor Society eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr Nitja Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research.
For more information, visit LACNETS.org/podcast/24.
For more information, visit LACNETS.org.
36 episoder
Del
